Skip to main content

Main menu

  • Home
  • Current issue
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
  • Alerts
  • Subscriptions

Does attempting talc pleurodesis affect subsequent indwelling pleural catheter (IPC)-related non-draining septated pleural effusion and IPC-related spontaneous pleurodesis?

Rachelle Asciak, Rachel M. Mercer, Robert J. Hallifax, Maged Hassan, Eihab Bedawi, David McCracken, Nikolaos I. Kanellakis, John M. Wrightson, Ioannis Psallidas, Najib M. Rahman
ERJ Open Research 2019 5: 00208-2018; DOI: 10.1183/23120541.00208-2018
Rachelle Asciak
Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel M. Mercer
Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Hallifax
Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maged Hassan
Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maged Hassan
Eihab Bedawi
Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David McCracken
Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolaos I. Kanellakis
Laboratory of Pleural and Lung Cancer Translational Research, Nuffield Dept of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John M. Wrightson
Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioannis Psallidas
Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Najib M. Rahman
Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Prior talc pleurodesis does not result in worsened outcomes from subsequent indwelling pleural catheter use, and patients should not be dissuaded from choosing talc as a primary treatment for recurrent pleural effusion. http://ow.ly/qAAC30mYmr3

To the Editor:

Malignant pleural effusions (MPE) are common and associated with disabling symptoms, and large hospitalisation costs [1]. Current management of recurrent MPE is symptomatic, with chest drain and talc pleurodesis, or indwelling pleural catheter (IPC) insertion. IPCs are an increasingly attractive option in patients wishing to avoid hospitalisation as they reduce initial length of stay [2, 3], but require repeated domiciliary drainage. Other patients opt for talc pleurodesis because, if successful, it represents a one-time definitive procedure, but it has a modest failure rate (20–30%) [4]. In the case of talc pleurodesis failure, IPC insertion is usually advocated with the consequence that a subset of patients with IPC in situ will have previously received ipsilateral intrapleural talc. IPCs are also increasingly being used in patients with recurrent benign pleural effusions (non-MPE) [5, 6].

Some patients with IPC will go on to have spontaneous pleurodesis, allowing the IPC to be removed. This occurs in about 40% of patients [7, 8]. Fibrin deposition within the pleural space facilitates IPC-related spontaneous pleurodesis, but it can also induce septations and loculations, impairing effective fluid drainage in patients with symptoms of accumulated fluid. Non-draining symptomatic septated IPC-related pleural effusions (NSSIPE) complicate up to 14% of IPC insertions [8–11]. Non-draining MPEs are associated with higher levels of pleural fluid lactate dehydrogenase and systemic C-reactive protein, indicating an association between non-draining MPEs and increased pleural fluid metabolic activity and systemic inflammation. Septations are thought to arise because of activation of the coagulation cascade, possibly as a result of repeated fluid drainage, the pleural tumour or the IPC itself, resulting in deposition of fibrin and formation of fibrinous strands within the pleural fluid [9, 10, 12], and failure of talc pleurodesis has been associated with increased pleural fibrinolytic activity [13]. Given the larger pleural tumour bulk and greater area of pleural involvement with mesothelioma than with other MPEs [14], mesothelioma may be associated with increased risk of fibrin deposition.

The aim of instilling talc within the pleural space is to induce an inflammatory reaction, leading to fibrosis and adhesion formation between the visceral and parietal pleura. A prior talc pleurodesis attempt in a patient with an IPC may therefore potentially be associated with increased risk of septation formation, and there is therefore clinical uncertainty as to whether IPC insertion should be the treatment of choice for recurrent pleural effusions, rather than talc.

This study aimed to assess whether or not prior failed talc pleurodesis is associated with increased risk of NSSIPE.

All IPC insertion records (January 2008 to April 2017) were analysed retrospectively. Standard management in our unit during this time was to offer patients with recurrent pleural effusions a choice between 1) chest drain insertion with talc pleurodesis and 2) IPC insertion as first-line management for recurrent pleural effusion (and only after optimising medical management in benign (non-MPE) effusions). Some patients with macroscopic evidence of malignancy at thoracoscopy would have had talc poudrage during the same procedure. In cases of non-expandable lung, patients were not offered the option of talc pleurodesis and IPC insertion was advocated.

Data on previous ipsilateral pleural procedures, including attempted talc pleurodesis, and details on IPC outcomes were collected from medical records. NSSIPE was defined as symptomatic pleural fluid collection with septations evident on pleural ultrasound performed by a pleural physician (minimum Royal College of Physicians level 1 thoracic ultrasound competence), in the context of a non-draining patent IPC. IPC-related spontaneous pleurodesis was defined as minimal or no output via a patent IPC, associated with minimal or no residual effusion on chest radiography or ultrasound.

There were 202 recorded IPC insertions: non-MPE group (n=21, mean±sd age 70±10.8 years and 29% (n=6) female; underlying causes: hepatic hydrothorax (3% overall), benign pleuritis (3%), heart failure (2%) and other (2.5%)); and MPE group (n=181, mean±sd age 68±13.9 years (p=0.4) and 48% female (n=87) (p=0.09)).

There was no statistically significant difference in rates of NSSIPE between IPCs with prior ipsilateral talc pleurodesis (two (2.9%) out of 68 patients,) and those without (six (5.3%) out of 113 patients) (p=0.5, Fisher's exact test), between non-MPE (n=0) and MPE (eight (4.4%) out of 181) (p=0.4), and between mesothelioma MPE (three (7.9%) out of 38) and non-mesothelioma MPE (five (3.5%) out of 143) (p=0.4).

The total number of NSSIPEs was eight (4%) out of the 202 recorded IPC insertions. Of these, two (25%) had a heterogeneously septated pleural effusion identified on ultrasound at IPC insertion, and neither had received prior intrapleural talc, while the other six (75%) developed new septation after IPC insertion. Three NSSIPEs were moderate-to-large effusions, and were treated with intrapleural fibrinolytics (two out of two of the patients who had received prior talc, and one out of six of the patients who had not received prior talc). The rest were small effusions and were not treated with intrapleural fibrinolytics. The results are summarised in figure 1.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Rate of non-draining symptomatic septated IPC-related pleural effusions (NSSIPE) in patients who had a prior talc pleurodesis attempt and those who had not, and in patients with mesothelioma and non-mesothelioma malignant pleural effusion (MPE). IPC: indwelling pleural catheter.

Three IPC insertions (n=1 non-MPE group, n=2 MPE group) were excluded from analysis of spontaneous pleurodesis because of insufficient data on reason and date of IPC removal (n=20 and n=179, respectively, were analysed further). In the non-MPE group, seven (35%) out of 20 had received prior talc once. In the MPE group, 68 (36%) out of 179 had received prior talc (n=60 received talc once and n=8 received talc twice). Overall, 75 (37.7%) out of 199 had received prior talc, and 25 (33.3%) out of 75 achieved spontaneous pleurodesis with a median (interquartile range (IQR)) of 105 (88.5) days to IPC removal, compared with 40 (32.3%) out of 124 spontaneous pleurodeses in IPC insertions without prior talc (p=0.9, Chi-squared=0.02, df=1), with a median (IQR) of 104.5 (87) days to IPC removal (p=0.3, two-tailed Mann–Whitney U-test).

Understanding whether or not prior intrapleural talc increases the risk of future NSSIPE or IPC-related spontaneous pleurodesis is helpful in the optimal selection and order of intervention for patients. In this study, there was no difference in rates of NSSIPE between patients who had received prior talc and those who had not, whether they had MPE or non-MPE, and whether the underlying cause for the MPE was mesothelioma or another primary cancer. There was no difference in rate of, or time to, IPC-related spontaneous pleurodesis between patients who had previous failed talc pleurodesis and those who chose IPC in the first instance, whether the patient had MPE or non-MPE. Interestingly, the 4% overall NSSIPE rate in this study population was lower than that quoted in literature (up to 14%) [8–11], and only three (38%) out of eight NSSIPEs were treated with intrapleural fibrinolytics.

Non-draining effusions with pleural septation and fibrin deposition are associated with increased pleural metabolic activity and systemic inflammation. The aim of giving talc is to induce an inflammatory response within the pleural space, leading to adhesion formation with subsequent pleurodesis. The results of this study raise interesting questions: in cases of failed talc pleurodesis, why is it that talc is not associated with increased rates of NSSIPE or of subsequent IPC-related spontaneous pleurodesis? It may be that if a patient is unable to mount an adequate initial immune response to talc, and therefore has failure in response to talc pleurodesis, then it is also not possible to mount an adequate immune reaction to talc to form adhesions and septations to develop NSSIPE. Further studies are needed to investigate whether the pleural space in certain patients is inherently resistant to different forms of pleurodesis.

This study is limited by the retrospective study design and the relatively small numbers of NSSIPE. The latter is not surprising given that a recent randomised control trial of intrapleural fibrinolytics in non-draining MPEs needed to screen almost 700 patients to randomise 71 non-draining MPEs [15]. However, the small numbers do indicate that a clinician would not commonly encounter NSSIPE, whether the patient has had a prior talc pleurodesis attempt or not.

Talc pleurodesis remains an important alternative to IPC insertion in recurrent pleural effusion. The risk of subsequent NSSIPE should not be a reason to dissuade patients from choosing talc as a primary treatment for recurrent pleural effusion, it appears that prior talc pleurodesis does not result in worsened outcomes from subsequent IPC use.

Footnotes

  • Conflict of interest: R. Asciak has nothing to disclose.

  • Conflict of interest: R.M. Mercer has nothing to disclose.

  • Conflict of interest: R.J. Hallifax has nothing to disclose.

  • Conflict of interest: M. Hassan has nothing to disclose.

  • Conflict of interest: E. Bedawi has nothing to disclose.

  • Conflict of interest: D. McCracken has nothing to disclose.

  • Conflict of interest: N.I. Kanellakis has nothing to disclose.

  • Conflict of interest: J.M. Wrightson has nothing to disclose.

  • Conflict of interest: I. Psallidas has nothing to disclose.

  • Conflict of interest: N.M. Rahman reports he acts as an external consultant to Rocket Medical PLC.

  • Received November 6, 2018.
  • Accepted November 7, 2018.
  • Copyright ©ERS 2019

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Taghizadeh N,
    2. Fortin M,
    3. Tremblay A
    . US hospitalizations for malignant pleural effusions: data from the 2012 national inpatient sample. Chest 2017; 151: 845–854.
    OpenUrl
  2. ↵
    1. Davies HE,
    2. Mishra EK,
    3. Kahan BC, et al.
    Effect of an indwelling pleural catheter versus chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307: 2383–2389.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Thomas R,
    2. Fysh ETH,
    3. Smith NA, et al.
    Effect of an indwelling pleural catheter versus talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA 2017; 318: 1903–1912.
    OpenUrl
  4. ↵
    1. Bibby AC,
    2. Dorn P,
    3. Psallidas I, et al.
    ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J 2018; 52: 1800349.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Bintcliffe OJ,
    2. Arnold DT,
    3. Maskell NA
    . Indwelling pleural catheters for benign pleural effusions. Curr Respir Care Rep 2014; 3: 61–70.
    OpenUrlCrossRef
  6. ↵
    1. Patil M,
    2. Dhillon SS,
    3. Attwood K, et al.
    Management of benign pleural effusions using indwelling pleural catheters: a systematic review and meta-analysis. Chest 2017; 151: 626–635.
    OpenUrl
  7. ↵
    1. Fysh ETH,
    2. Waterer GW,
    3. Kendall PA, et al.
    indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest 2012; 142: 394–400.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Tremblay A,
    2. Michaud G
    . Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006; 129: 362–368.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Banka R,
    2. Terrington D,
    3. Mishra EK
    . Management of septated malignant pleural effusions. Curr Pulmonol Rep 2018; 7: 1–5.
    OpenUrl
  10. ↵
    1. Lui MMS,
    2. Thomas R,
    3. Lee YCG
    . Complications of indwelling pleural catheter use and their management. BMJ Open Respir Res 2016; 3: e000123.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Thomas R,
    2. Piccolo F,
    3. Miller D, et al.
    Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: a multicenter observational study. Chest 2015; 148: 746–751.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Chung C-L,
    2. Chen Y-C,
    3. Chang S-C
    . Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion. Chest 2003; 123: 1188–1195.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Rodriguez-Panadero F,
    2. Segado A,
    3. Martin Juan J, et al.
    Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med 1995; 151: 785–790.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Fysh ETH,
    2. Tan SK,
    3. Read CA, et al.
    Pleurodesis outcome in malignant pleural mesothelioma. Thorax 2013; 68: 594–596.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Mishra EK,
    2. Clive AO,
    3. Wills GH, et al.
    Randomized controlled trial of urokinase versus placebo for nondraining malignant pleural effusion. Am J Respir Crit Care Med 2018; 197: 502–508.
    OpenUrl
View Abstract
Next
Back to top
Vol 5 Issue 1 Table of Contents
ERJ Open Research: 5 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Does attempting talc pleurodesis affect subsequent indwelling pleural catheter (IPC)-related non-draining septated pleural effusion and IPC-related spontaneous pleurodesis?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Does attempting talc pleurodesis affect subsequent indwelling pleural catheter (IPC)-related non-draining septated pleural effusion and IPC-related spontaneous pleurodesis?
Rachelle Asciak, Rachel M. Mercer, Robert J. Hallifax, Maged Hassan, Eihab Bedawi, David McCracken, Nikolaos I. Kanellakis, John M. Wrightson, Ioannis Psallidas, Najib M. Rahman
ERJ Open Research Feb 2019, 5 (1) 00208-2018; DOI: 10.1183/23120541.00208-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Does attempting talc pleurodesis affect subsequent indwelling pleural catheter (IPC)-related non-draining septated pleural effusion and IPC-related spontaneous pleurodesis?
Rachelle Asciak, Rachel M. Mercer, Robert J. Hallifax, Maged Hassan, Eihab Bedawi, David McCracken, Nikolaos I. Kanellakis, John M. Wrightson, Ioannis Psallidas, Najib M. Rahman
ERJ Open Research Feb 2019, 5 (1) 00208-2018; DOI: 10.1183/23120541.00208-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Trends of MDR-TB clustering in Portugal
  • PVOD prevalence in SSc patients undergoing lung transplantation
  • IQOS exposure impairs human airway cell homeostasis
Show more Original research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Collections
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2019 by the European Respiratory Society